Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial

Vaglio, Augusto; Palmisano, Alessandra; Alberici, Federico; Maggiore, Umberto; Ferretti, Stefania; Cobelli, Rocco; Ferrozzi, F; Corradi, Domenico; Salvarani, Carlo; Buzio, Carlo

doi:10.1016/s0140-6736(11)60934-3

Cited by 203 publications

(163 citation statements)

References 43 publications

Supporting

Mentioning

142

Contrasting

Unclassified

Order By: Relevance

“…This disease is rare, with an incidence rate of 1 in 200,000 (2). RPF typically presents in individuals 40-60 years of age and is 2-3 times more common in males than females (3,4).…”

Section: Introductionmentioning

confidence: 99%

Retroperitoneal fibrosis and constrictive pericarditis-IgG4 related diseases: A case report

Terzić

Spasić

Djuric

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Retroperitoneal fibrosis (RPF) is a rare disease characterized by infiltration of inflammatory cells and deposition of thickened fibrous tissues. The present study presents the case of a 53-year-old patient treated for generalized weakness and fatigue for 1 year prior to hospitalization. A cardiac ultrasound revealed pericardial effusion that required pericardiocentesis, during which 1,400 ml serous fluid with the characteristics of an exudate was aspirated. A pericardiectomy was performed due to persistent effusion and histological examination indicated pericardial fibrosis. A thoracic-abdominal computed tomography scan revealed the presence of retroperitoneal fibrosis. The patient was treated with corticosteroids and azathioprine. Follow-up examinations showed a significant reduction in the amount of abdominal fibrous tissue and no increase in pericardial effusion 1 year following the end of treatment. The patient continues to have regular follow-up control examinations with a cardiologist and nephrologist.

show abstract

“…This disease is rare, with an incidence rate of 1 in 200,000 (2). RPF typically presents in individuals 40-60 years of age and is 2-3 times more common in males than females (3,4).…”

Section: Introductionmentioning

confidence: 99%

Retroperitoneal fibrosis and constrictive pericarditis-IgG4 related diseases: A case report

Terzić

Spasić

Djuric

et al. 2017

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

show abstract

“…In a randomized controlled trial, after achieving remission with high-dose prednisolone as an induction therapy, patients were divided into 2 groups and followed up with CS (prednisone) or TMX mono therapy for 8 months. In this study, maintenance therapy with CS was associated with lower relapse rates, with a higher side effect profile than TMX group (21). Van der Bilt et al…”

Section: Discussionmentioning

confidence: 47%

“…After the urinary system decompression by PNT or DJ stent, there are two options as first line medical treatment (20). CS alone or CS with tamoxifen (TMX) can be used as first line therapy (21). The second step is the addition of drugs such as immunosuppressive azathioprine (AZA), mycophenol mofetil, rituximab, bortezomip, cyclophosphamide, cyclo sporine in the course of treatment or relapse (22).…”

Section: Discussionmentioning

confidence: 99%

A rare cause of acute post renal failure: Retroperitoneal fibrosis

Şeker

Ekşi

Çolakoğlu

et al. 2017

Arch Ital Urol Androl

View full text Add to dashboard Cite

show abstract

“…Cette étude a montré que le tamoxifène est moins efficace que la prednisone en présence de récidives. 42 D'autres stratégies d'épargne cortisonique ont été essayées avec le mofétilmycophénolate, le cyclophosphamide et l'azathioprine. [43][44][45] Les stratégies associant la prednisone et le mofétilmycophénolate ou l'azathioprine ont donné de bons résultats.…”

Section: Traitement Médicalunclassified

Fibrose rétropéritonéale : revue de littérature

Jakhlal

Elghazoui

Jabbour

et al. 2017

CUAJ

View full text Add to dashboard Cite

RésuméLa fibrose rétropéritonéale (FRP) est une maladie rare, caractérisée par la présence d'un tissu fibro-inflammatoire aberrant qui se forme souvent autour de la portion sous-rénale de l'aorte abdominale et des artères iliaques. Une obstruction urétérale est souvent observée. Récemment, la FPR idiopathique est rapportée parmi les manifestations de la maladie à IgG4. L'imagerie joue un rôle important dans le diagnostic de la FRP. Les glucocorticoïdes sont le traitement de référence, utilisés en monothérapie ou en association avec d'autres agents médicamenteux. En cas d'échec des mesures conservatrices, la chirurgie peut être proposée. Récemment, des techniques minimalement invasives ont été utilisées.

show abstract

Prednisone versus tamoxifen in patients with idiopathic retroperitoneal fibrosis: an open-label randomised controlled trial

Cited by 203 publications

References 43 publications

Retroperitoneal fibrosis and constrictive pericarditis-IgG4 related diseases: A case report

Retroperitoneal fibrosis and constrictive pericarditis-IgG4 related diseases: A case report

A rare cause of acute post renal failure: Retroperitoneal fibrosis

Fibrose rétropéritonéale : revue de littérature

Contact Info

Product

Resources

About